Evidence map›Paper›PMID 41301512›Full record

ArticleBiomolecules2025

Screening and Characterization of TAT-Fused Nanobodies Targeting Bovine Viral Diarrhea Virus NS3/NS5A for Antiviral Application.

Qianqian Dong, Yangyang Xiao, Zhao Liu, Wenxiang Zhang, Aodi Wu, Hanwen Zhang, Jinliang Sheng

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biomolecules, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Qianqian DongCollege of Animal Science and Technology, Shihezi University, Shihezi 832003, China.
Yangyang XiaoCollege of Animal Science and Technology, Shihezi University, Shihezi 832003, China.
Zhao LiuCollege of Animal Science and Technology, Shihezi University, Shihezi 832003, China.
Wenxiang ZhangCollege of Animal Science and Technology, Shihezi University, Shihezi 832003, China.ORCID 0009-0004-6008-2535
Aodi WuCollege of Animal Science and Technology, Shihezi University, Shihezi 832003, China.
Hanwen ZhangCollege of Animal Science and Technology, Shihezi University, Shihezi 832003, China.
Jinliang ShengCollege of Animal Science and Technology, Shihezi University, Shihezi 832003, China.

Funding

National Natural Science Foundation 32460872Science and Technology Programme Project of the Eighth Division 2024SF02
6 · The paper itself

Abstract

Bovine viral diarrhea virus (BVDV) is a major pathogen responsible for significant economic losses in the global cattle industry. The diverse transmission routes and the characteristics of asymptomatic infections make it difficult to contain the spread; there is an urgent need to develop new effective antiviral strategies. Nanobodies (Nbs) have become a promising new type of antiviral agent due to their advantages, including small molecular size, stable structure, high specificity, and ease of production. This study successfully screened a specific nanobody, Nb7, targeting the key functional protein NS5A of BVDV using phage display technology. Furthermore, the nanobody was effectively delivered into Madin-Darby bovine kidney (MDBK) cells by fusing it with the cell-penetrating peptide TAT. The results demonstrate that TAT-Nb7, specifically targeting the non-structural protein NS5A of BVDV, significantly inhibits viral replication in MDBK cells. In conclusion, this study indicates that TAT-Nb7 holds promise as a therapeutic candidate for the prevention and control of BVDV infection.

Indexed as

Antiviral AgentsDiarrhea Viruses, Bovine ViralSingle-Domain AntibodiesViral Nonstructural ProteinsAnimalsCattleCell LineVirus ReplicationAntiviral AgentsSingle-Domain AntibodiesViral Nonstructural Proteinsantiviralbovine viral diarrhea virus (BVDV)nanobodytrans-activator of transcription (TAT)

Identifiers

PMID41301512
PMCPMC12650317

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.